{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:22:43Z","timestamp":1782944563011,"version":"3.54.5"},"reference-count":41,"publisher":"Tohoku University Medical Press","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2025]]},"DOI":"10.1620\/tjem.2024.j124","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T22:11:22Z","timestamp":1730931082000},"page":"229-237","source":"Crossref","is-referenced-by-count":1,"title":["Effects of 15 Years of Continuous Treatment with Bisphosphonate on Japanese Postmenopausal Osteoporosis Patients: An Observational Study"],"prefix":"10.1620","volume":"265","author":[{"given":"Kousuke","family":"Iba","sequence":"first","affiliation":[{"name":"Department of Musculoskeletal Anti-aging Medicine, Sapporo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Hanaka","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Anti-aging Medicine, Sapporo Medical University"},{"name":"Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Emori","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Takashima","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Anti-aging Medicine, Sapporo Medical University"},{"name":"Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Teramoto","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Takada","sequence":"additional","affiliation":[{"name":"Sapporo Maruyama Orthopaedic Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Abrahamsen, B., Eiken, P., Prieto-Alhambra, D. &amp; Eastell, R.(2016)  Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study.  <i>BMJ<\/i>,  353,  i3365.","DOI":"10.1136\/bmj.i3365"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Adams, A.L., Adams, J.L., Raebel, M.A., Tang, B.T., Kuntz, J.L., Vijayadeva, V., McGlynn, E.A. &amp; Gozansky, W.S.(2018)  Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study.  <i>J. Bone Miner. Res.<\/i>,  33,  1252-1259.","DOI":"10.1002\/jbmr.3420"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Adler, R.A., El-Hajj Fuleihan, G., Bauer, D.C., Camacho, P.M., Clarke, B.L., Clines, G.A., Compston, J.E., Drake, M.T., Edwards, B.J., Favus, M.J., Greenspan, S.L., McKinney, R. Jr., Pignolo, R.J. &amp; Sellmeyer, D.E.(2016)  Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.  <i>J. Bone Miner. Res.<\/i>,  31,  16-35.","DOI":"10.1002\/jbmr.2708"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Axelsson, K.F., Wallander, M., Johansson, H., Lundh, D. &amp; Lorentzon, M.(2017)  Hip fracture risk and safety with alendronate treatment in the oldest-old.  <i>J. Intern. Med.<\/i>,  282,  546-559.","DOI":"10.1111\/joim.12678"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Bauer, D.C. &amp; Abrahamsen, B.(2021)  Bisphosphonate Drug Holidays in Primary Care: When and What to Do Next?.  <i>Curr. Osteoporos. Rep.<\/i>,  19,  182-188.","DOI":"10.1007\/s11914-021-00660-4"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Beck, T.J.  (2007)  Extending DXA beyond bone mineral density: understanding hip structure analysis.  <i>Curr. Osteoporos. Rep.<\/i>,  5,  49-55.","DOI":"10.1007\/s11914-007-0002-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Black, D.M., Geiger, E.J., Eastell, R., Vittinghoff, E., Li, B.H., Ryan, D.S., Dell, R.M. &amp; Adams, A.L.(2020)  Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.  <i>N. Engl. J. Med.<\/i>,  383,  743-753.","DOI":"10.1056\/NEJMoa1916525"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Black, D.M., Reid, I.R., Boonen, S., Bucci-Rechtweg, C., Cauley, J.A., Cosman, F., Cummings, S.R., Hue, T.F., Lippuner, K., Lakatos, P., Leung, P.C., Man, Z., Martinez, R.L., Tan, M., Ruzycky, M.E.,  et al. (2012)  The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).  <i>J. Bone Miner. Res.<\/i>,  27,  243-254.","DOI":"10.1002\/jbmr.1494"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Black, D.M., Schwartz, A.V., Ensrud, K.E., Cauley, J.A., Levis, S., Quandt, S.A., Satterfield, S., Wallace, R.B., Bauer, D.C., Palermo, L., Wehren, L.E., Lombardi, A., Santora, A.C., Cummings, S.R. &amp; Group, F.R.(2006)  Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.  <i>JAMA<\/i>,  296,  2927-2938.","DOI":"10.1001\/jama.296.24.2927"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Bone, H.G., Hosking, D., Devogelaer, J.P., Tucci, J.R., Emkey, R.D., Tonino, R.P., Rodriguez-Portales, J.A., Downs, R.W., Gupta, J., Santora, A.C., Liberman, U.A. &amp; Alendronate Phase, I.I.I.O.T.S.G.(2004)  Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women.  <i>N. Engl. J. Med.<\/i>,  350,  1189-1199.","DOI":"10.1056\/NEJMoa030897"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Bonnick, S., De Villiers, T., Odio, A., Palacios, S., Chapurlat, R., DaSilva, C., Scott, B.B., Le Bailly De Tilleghem, C., Leung, A.T. &amp; Gurner, D.(2013)  Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.  <i>J. Clin. Endocrinol. Metab.<\/i>,  98,  4727-4735.","DOI":"10.1210\/jc.2013-2020"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Cranney, A., Tugwell, P., Adachi, J., Weaver, B., Zytaruk, N., Papaioannou, A., Robinson, V., Shea, B., Wells, G., Guyatt, G., Osteoporosis Methodology, G. &amp; The Osteoporosis Research Advisory, G.(2002)  Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis.  <i>Endocr. Rev.<\/i>,  23,  517-523.","DOI":"10.1210\/er.2001-3002"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Dell, R.M., Adams, A.L., Greene, D.F., Funahashi, T.T., Silverman, S.L., Eisemon, E.O., Zhou, H., Burchette, R.J. &amp; Ott, S.M.(2012)  Incidence of atypical nontraumatic diaphyseal fractures of the femur.  <i>J. Bone Miner. Res.<\/i>,  27,  2544-2550.","DOI":"10.1002\/jbmr.1719"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Ebetino, F.H., Hogan, A.M., Sun, S., Tsoumpra, M.K., Duan, X., Triffitt, J.T., Kwaasi, A.A., Dunford, J.E., Barnett, B.L., Oppermann, U., Lundy, M.W., Boyde, A., Kashemirov, B.A., McKenna, C.E. &amp; Russell, R.G.(2011)  The relationship between the chemistry and biological activity of the bisphosphonates.  <i>Bone<\/i>,  49,  20-33.","DOI":"10.1016\/j.bone.2011.03.774"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Ensrud, K.E., Barrett-Connor, E.L., Schwartz, A., Santora, A.C., Bauer, D.C., Suryawanshi, S., Feldstein, A., Haskell, W.L., Hochberg, M.C., Torner, J.C., Lombardi, A., Black, D.M. &amp; Fracture Intervention Trial Long-Term Extension Research, G.(2004)  Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.  <i>J. Bone Miner. Res.<\/i>,  19,  1259-1269.","DOI":"10.1359\/JBMR.040326"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Hagino, H., Sugimoto, T., Tanaka, S., Sasaki, K., Sone, T., Nakamura, T., Soen, S. &amp; Mori, S.(2021)  A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05.  <i>Osteoporos. Int.<\/i>,  32,  2301-2311.","DOI":"10.1007\/s00198-021-05996-2"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Iba, K., Takada, J., Sonoda, T. &amp; Yamashita, T.(2020)  Effect of continuous long-term treatment for 10 years with bisphosphonate on Japanese osteoporosis patients.  <i>J. Bone Miner. Metab.<\/i>,  38,  240-247.","DOI":"10.1007\/s00774-019-01049-1"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Kline, G.A., Morin, S.N., Lix, L.M. &amp; Leslie, W.D.(2023)  A Population-Based Registry Study of Extended Bisphosphonate Use: Minimal Shift After Landmark Publications About Shorter Treatment Duration.  <i>J. Bone Miner. Res.<\/i>,  38,  1435-1442.","DOI":"10.1002\/jbmr.4885"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Lo, J.C., Grimsrud, C.D., Ott, S.M., Chandra, M., Hui, R.L. &amp; Ettinger, B.(2019)  Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure.  <i>Osteoporos. Int.<\/i>,  30,  2515-2520.","DOI":"10.1007\/s00198-019-05112-5"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Mahjoub, Z., Jean, S., Leclerc, J.T., Brown, J.P., Boulet, D., Pelet, S., Grondin, C., Dumont, J., Belzile, E.L. &amp; Michou, L.(2016)  Incidence and Characteristics of Atypical Femoral Fractures: Clinical and Geometrical Data.  <i>J. Bone Miner. Res.<\/i>,  31,  767-776.","DOI":"10.1002\/jbmr.2748"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Michalsk\u00e1, D., Stepan, J.J., Basson, B.R. &amp; Pavo, I.(2006)  The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis.  <i>J. Clin. Endocrinol. Metab.<\/i>,  91,  870-877.","DOI":"10.1210\/jc.2004-2212"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Neer, R.M., Arnaud, C.D., Zanchetta, J.R., Prince, R., Gaich, G.A., Reginster, J.Y., Hodsman, A.B., Eriksen, E.F., Ish-Shalom, S., Genant, H.K., Wang, O. &amp; Mitlak, B.H.(2001)  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.  <i>N. Engl. J. Med.<\/i>,  344,  1434-1441.","DOI":"10.1056\/NEJM200105103441904"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Oda, T., Jodicke, A.M., Robinson, D.E., Delmestri, A., Keogh, R.H. &amp; Prieto-Alhambra, D.(2022)  Oral Bisphosphonates Are Associated With Increased Risk of Severe Acute Kidney Injury in Elderly Patients With Complex Health Needs: A Self-Controlled Case Series in the United Kingdom.  <i>J. Bone Miner. Res.<\/i>,  37,  1270-1278.","DOI":"10.1002\/jbmr.4573"},{"key":"24","unstructured":"Orimo, H. (2015)  Japanese guidelines for prevention and treatment of osteoporosis.  Life Science, Tokyo, Japan (in Japanese)."},{"key":"25","doi-asserted-by":"crossref","unstructured":"Papapoulos, S., Lippuner, K., Roux, C., Lin, C.J., Kendler, D.L., Lewiecki, E.M., Brandi, M.L., Czerwinski, E., Franek, E., Lakatos, P., Mautalen, C., Minisola, S., Reginster, J.Y., Jensen, S., Daizadeh, N.S.,  et al. (2015)  The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.  <i>Osteoporos. Int.<\/i>,  26,  2773-2783.","DOI":"10.1007\/s00198-015-3234-7"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Poutoglidou, F., Samoladas, E., Raikos, N. &amp; Kouvelas, D.(2022)  Efficacy and safety of anti-sclerostin antibodies in the treatment of osteoporosis: A meta-analysis and systematic review.  <i>J. Clin. Densitom.<\/i>,  25,  401-415.","DOI":"10.1016\/j.jocd.2021.11.005"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Qaseem, A., Forciea, M.A., McLean, R.M., Denberg, T.D., Clinical Guidelines Committee of the American College of, P., Barry, M.J., Cooke, M., Fitterman, N., Harris, R.P., Humphrey, L.L., Kansagara, D., McLean, R.M., Mir, T.P. &amp; Schunemann, H.J.(2017)  Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians.  <i>Ann. Intern. Med.<\/i>,  166,  818-839.","DOI":"10.7326\/M15-1361"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Saag, K., Cosman, F., De Villiers, T., Langdahl, B., Scott, B.B., Denker, A.E., Pong, A. &amp; Santora, A.C.(2021)  Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis.  <i>Osteoporos. Int.<\/i>,  32,  1879-1888.","DOI":"10.1007\/s00198-020-05785-3"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Saag, K.G., Petersen, J., Brandi, M.L., Karaplis, A.C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P.D. &amp; Grauer, A.(2017)  Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.  <i>N. Engl. J. Med.<\/i>,  377,  1417-1427.","DOI":"10.1056\/NEJMoa1708322"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Schilcher, J., Koeppen, V., Aspenberg, P. &amp; Michaelsson, K.(2015)  Risk of atypical femoral fracture during and after bisphosphonate use.  <i>Acta Orthop.<\/i>,  86,  100-107.","DOI":"10.3109\/17453674.2015.1004149"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Schilcher, J., Michaelsson, K. &amp; Aspenberg, P.(2011)  Bisphosphonate use and atypical fractures of the femoral shaft.  <i>N. Engl. J. Med.<\/i>,  364,  1728-1737.","DOI":"10.1056\/NEJMoa1010650"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Schwartz, A.V., Bauer, D.C., Cummings, S.R., Cauley, J.A., Ensrud, K.E., Palermo, L., Wallace, R.B., Hochberg, M.C., Feldstein, A.C., Lombardi, A., Black, D.M. &amp; Group, F.R.(2010)  Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial.  <i>J. Bone Miner. Res.<\/i>,  25,  976-982.","DOI":"10.1002\/jbmr.11"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Shane, E., Burr, D., Abrahamsen, B., Adler, R.A., Brown, T.D., Cheung, A.M., Cosman, F., Curtis, J.R., Dell, R., Dempster, D.W., Ebeling, P.R., Einhorn, T.A., Genant, H.K., Geusens, P., Klaushofer, K.,  et al. (2014)  Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.  <i>J. Bone Miner. Res.<\/i>,  29,  1-23.","DOI":"10.1002\/jbmr.1998"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Shiraki, M., Kushida, K., Fukunaga, M., Kishimoto, H., Taga, M., Nakamura, T., Kaneda, K., Minaguchi, H., Inoue, T., Morii, H., Tomita, A., Yamamoto, K., Nagata, Y., Nakashima, M. &amp; Orimo, H.(1999)  A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group.  <i>Osteoporos. Int.<\/i>,  10,  183-192.","DOI":"10.1007\/s001980050214"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Siu, A., Allore, H., Brown, D., Charles, S.T. &amp; Lohman, M.(2019)  National Institutes of Health Pathways to Prevention Workshop: Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention.  <i>Ann. Intern. Med.<\/i>,  171,  51-57.","DOI":"10.7326\/M19-0961"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Starr, J., Tay, Y.K.D. &amp; Shane, E.(2018)  Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures.  <i>Curr. Osteoporos. Rep.<\/i>,  16,  519-529.","DOI":"10.1007\/s11914-018-0464-6"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Takada, J., Beck, T.J., Iba, K. &amp; Yamashita, T.(2007)  Structural trends in the aging proximal femur in Japanese postmenopausal women.  <i>Bone<\/i>,  41,  97-102.","DOI":"10.1016\/j.bone.2007.04.178"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Takada, J., Katahira, G., Iba, K., Yoshizaki, T. &amp; Yamashita, T.(2011)  Hip structure analysis of bisphosphonate-treated Japanese postmenopausal women with osteoporosis.  <i>J. Bone Miner. Metab.<\/i>,  29,  458-465.","DOI":"10.1007\/s00774-010-0242-8"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Wang, M., Wu, Y.F. &amp; Girgis, C.M.(2022)  Bisphosphonate Drug Holidays: Evidence From Clinical Trials and Real-World Studies.  <i>JBMR Plus<\/i>,  6,  e10629.","DOI":"10.1002\/jbm4.10629"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Watts, N.B., Chines, A., Olszynski, W.P., McKeever, C.D., McClung, M.R., Zhou, X. &amp; Grauer, A.(2008)  Fracture risk remains reduced one year after discontinuation of risedronate.  <i>Osteoporos. Int.<\/i>,  19,  365-372.","DOI":"10.1007\/s00198-007-0460-7"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Wells, G.A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Robinson, V., Coyle, D. &amp; Tugwell, P.(2008)  Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.  <i>Cochrane Database Syst. Rev.<\/i>,  CD001155.","DOI":"10.1002\/14651858.CD001155.pub2"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/265\/4\/265_2024.J124\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T03:57:41Z","timestamp":1745639861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/265\/4\/265_2024.J124\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.2024.j124","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"2024.J124"}}